Overcoming antigen tolerance to develop GB22-45-2, an anti-DKK1 antibody for gastric cancer [0.03%]
克服抗原耐受性以开发用于胃癌的抗DKK1抗体GB22-45-2
Wenjun Zhang,Xiling Wei,Tianqi Yao et al.
Wenjun Zhang et al.
Background: Gastric cancer (GC) represents one of the most prevalent and lethal malignancies, however, current treatments have shown limited efficacy. Clinical investigations have revealed that Dickkopf-1 (DKK1)-high GC p...
Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional in vitro models of vascular inflammation [0.03%]
采用微流体和体内血管炎症模型评估新型VCAM-1抗体治疗潜力
Jessica R Pickett,Lucia F Zacchi,Binura Perera et al.
Jessica R Pickett et al.
Objective: Antibodies against vascular cell adhesion molecule (VCAM)-1 represent an attractive strategy for atherosclerosis and cardiovascular disease management due to their ability to selectively block leukocyte-endothe...
Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design [0.03%]
工程化新型轻链单域抗体以实现IgG格式双特异性抗体设计
Mingkai Wang,Qingyuan Xu,Yu Kong et al.
Mingkai Wang et al.
Background: As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing attention owing to their unique dual-targeting mechanisms. However, current b...
Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase [0.03%]
靶向前列腺特异性膜抗原和前列腺酸性磷酸酶的新型高亲和力全人源抗体的产生与表征
Claudia Comacchio,Stefanie K Pfister,Domenico Ravazza et al.
Claudia Comacchio et al.
Background: Prostate-specific membrane antigen (PSMA)-targeted therapies have revolutionized the management of patients with prostate cancer. However, not all patients benefit from such agents. Prostatic acid phosphatase ...
Yanlin Yu,Mitchell Ho
Yanlin Yu
CAR-T cell therapy has shown promise but is constrained by side effects and limited efficacy in treating solid tumors. Compared to CAR-T cells, CAR natural killer (NK) cells derived from multiple versatile sources exhibit more favorable saf...
Structure and function of therapeutic antibodies approved by the US FDA in 2024 [0.03%]
2024年美国FDA批准的治疗性抗体的结构与功能
William R Strohl
William R Strohl
In 2024, the Food and Drug Administration approved 47 new molecular entities (NMEs), including 15 therapeutic antibody-based molecules, marking the 30th anniversary of the first approved recombinant antibody. Ten of these were recombinant i...
Reprogramming the tumor microenvironment: synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors [0.03%]
肿瘤微环境的重编程：抗体-药物偶联物与免疫检查点抑制剂协同作用机制
Ling Yin,Shoubing Zhou,Hongliang Zhang et al.
Ling Yin et al.
The integration of antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) represents a paradigm shift in oncology, combining targeted cytotoxicity and adaptive immune activation to overcome resistance in refractory tumors....
Broadly reactive anti-VHH antibodies for characterizing, blocking, or activating nanobody-based CAR-T cells [0.03%]
用于表征、阻断或激活纳米抗体基CAR-T细胞的广谱抗VHH抗体
Scott McComb,Bianca Dupont,Alex Shepherd et al.
Scott McComb et al.
Background: Production of chimeric antigen receptor T cell (CAR-T) therapies depends on antibody reagents to label, isolate, and expand T cell products. We sought to create antibody tools specific for the variable domain ...
Qingyan Hu,Yunsong Frank Li
Qingyan Hu
Drug product formulation transforms active pharmaceutical ingredients into drug products, ensuring stability, manufacturability, efficacy, and patient safety. Driven by biotech advancements and patient needs, new antibody-based therapies an...
Antibody-drug conjugates in cancer and beyond: progress, promise, and perspectives [0.03%]
抗体偶联药物在癌症等领域取得的进展、展望及前景
Victor S Goldmacher
Victor S Goldmacher
Antibody-drug conjugates (ADCs) are transforming cancer therapy by combining antibody specificity with potent cytotoxic agents, enabling targeted tumor cell killing while minimizing systemic toxicity. This special collection of Antibody The...